Given the interest in developing appropriate models to test potential therapeutic compounds, we consider that our CLL-like mouse model provides an excellent model for carrying out pre-clinical testing of novel BCR-targeted agents, that may be translated towards the clinic. Here, BCR is linked to B-cell chronic lymphocytic leukemia.